Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Lantheus Holdings Inc. (LNTH)

NASDAQ: LNTH · In Vitro & In Vivo Diagnostic Substances · Bedford, MA

Our rating: Neutral

Neutral reaffirmed at $100.61, moderate conviction, November 6, 2026.

Breaks if: The Neutral call turns Positive if Lantheus reports two consecutive quarterly filings showing year-over-year revenue growth above 10%, confirming the top-line stall was temporary and a new growth driver is operating. It turns Cautious if revenue growth turns negative — below 0% — in any two of the next three quarterly filings while the P/E multiple remains above 22×, signaling the plateau has hardened into structural decline.

Key figures

Market value$6.7B
Revenue, last 12 months$1.6B
Net income, last 12 months$270M
Free cash flow, last 12 monthsn/a
Price to earnings24.7×
Free cash flow yieldn/a
Dividend yield0.0%
Operating margin18.6%
Return on equity21.8%
Beta to the S&P 5000.40
Volatility, annualized51.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$390M1.5%$0.33n/a
June 30, 2026$388M2.7%$1.11n/a
March 31, 2026$377M1.2%$1.80n/a
December 31, 2025$407M4.0%$0.81n/a
September 30, 2025$384M1.4%$0.41n/a
June 30, 2025$378M−4.1%$1.12n/a
March 31, 2025$373M0.8%$1.02n/a
December 31, 2024$391M10.5%$-0.19n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.